REGN vs RZC
Regeneron Pharmaceuticals Inc (REGN) versus 7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) common stock listed on US.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
RZC does not have a complete income-statement cache yet.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. RZC currently screens at market cap $0.
Not investment advice. Open the REGN and RZC stock pages for the full models.
Not investment advice.